Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Hanmi Pharmaceutical Company Limited clinical trials
Part of Hanmi Science Co., Ltd..
The registry lists 189 studies whose lead sponsor is Hanmi Pharmaceutical Company Limited. 10 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 19, 2026.
Keep track of what changes. Save the Hanmi Pharmaceutical Company Limited studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Hanmi Pharmaceutical Company Limited.
- Hanmi Pharmaceutical Company Limited189 studiesSame company
Something wrong?
Focus areas
Conditions Hanmi Pharmaceutical Company Limited leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 189. Browse all 189 →
- Study to Evaluate HM15275 in Subjects With Type 2 Diabetes MellitusRecruitingNCT07527650Phase 2
- Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid TumorsRecruitingNCT06234397Phase 1
- Effectiveness and Safety of Sequential Triple Combination Therapy (Amlodipine/Losartan/Chlorthalidone) in Korean Patients With HypertensionRecruitingNCT07784296
- Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF SubjectsRecruitingNCT04775706Phase 2
- A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential HypertensionNot yet recruitingNCT07660796Phase 3
- A Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and DapagliflozinRecruitingNCT07379333Phase 3
- A Single and Multiple Ascending Dose Study of HM17321 in Healthy and Obese ParticipantsRecruitingNCT07219589Phase 1
- Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant MelanomaRecruitingNCT07449754Phase 2
- A Study to Evaluate the Pharmacokinetics and Safety Between HIP2503 and HCP1306 in Healthy VolunteersNot yet recruitingNCT07297693Phase 1
- Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid TumorsRecruitingNCT06724016Phase 1
- Efocipegtrutide (HM15211) in Adults With Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH)CompletedNCT04505436Phase 2
- A Study to Evaluate Efficacy and Safety of HGP2304 in Essential Hypertension PatientsCompletedNCT06174766Phase 3
- HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)Active, not recruitingNCT04732416Phase 2
- Dose Escalation and Expansion Study of HM97662 in Advanced or Metastatic Solid TumorsActive, not recruitingNCT05598151Phase 1
- A Study to Evaluate Efficacy and Safety of HM11260C in Adult Obesity Patients Without Diabetes MellitusCompletedNCT06174779Phase 3
- Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes MellitusActive, not recruitingNCT07205900Phase 2
- A Study to Evaluate the Efficacy and Safety of HCP1004 in Chronic Low-Back Pain PatientsCompletedNCT06595004Phase 3
- FLX475 Combined With Pembrolizumab in Patients With Advanced or Metastatic Gastric CancerCompletedNCT04768686Phase 2
- A Phase 1 Study to Assess HM15275 in Healthy and Obese Subjects.CompletedNCT06481098Phase 1
- Phase 1 Study of PK and Safety of HM15912 (Sonefpeglutide) in Subjects With Normal and Severe Kidney FunctionCompletedNCT05711381Phase 1
- A Study to Evaluate the Drug-drug Interaction and Safety Between HCP1306, RLD2302 and RLD2102 in Healthy VolunteersCompletedNCT06518122Phase 1
- A Study to Evaluate the Effiacy and Safety of HIP0612 in Patients with Gastric UlcerCompletedNCT05656092Phase 3
- A Study to Evaluate Efficacy and Safety of HCP1803 Compared to RLD2001-1 in Patients with Essential HypertensionCompletedNCT06438172Phase 3
- Single Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15912(Sonefpeglutide) in Healthy Korean SubjectsCompletedNCT04076293Phase 1
- A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15211(Efocipegtrutide)CompletedNCT03374241Phase 1
- A First-in-Human, Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM15136(Efpegerglucagon) in Healthy SubjectsCompletedNCT04032782Phase 1
- A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLDCompletedNCT03744182Phase 1
- Study for Multiple Doses of HM15136(Efpegerglucagon) in Obese or Overweight Subjects With ComorbiditiesCompletedNCT04167553Phase 1
- A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1904 in Healthy Male Volunteers.CompletedNCT05407220Phase 1
- A Study to Evaluate the Pharmacokinetics and Safety Between HCP2303 and Co-administration of Each Component in Healthy Volunteers Under Fed ConditionsCompletedNCT06357910Phase 1
- A Study to Evaluate the Pharmacokinetics and Safety Between HCP2303 and Co-administration of Each Component in Healthy VolunteersCompletedNCT06346184Phase 1
- A Study to Evaluate the Pharmacokinetics and Safety Between HCP2201 and Co-administration of Each Component in Healty Male VolunteersCompletedNCT05737082Phase 1
- A Study to Evaluate the Efficacy and Safety of HCP2102 in Essential Hypertension PatientsCompletedNCT05450601Phase 3
- Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of HIP2105 to RLD2104 in Healthy VolunteersCompletedNCT04975711Phase 1
- Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of HIP1802 to HGP1705 in Healthy VolunteersCompletedNCT04324905Phase 1
- A Study to Evaluate Efficacy and Safety of HCP1803 in Patients With Essential HypertensionCompletedNCT05362110Phase 3
- Clinical Efficacy and Safety Evaluation of HCP1904-3 in Essential Hypertension PatientsCompletedNCT05199129Phase 3
- A Study to Evaluate the Pharmacokinetics and Safety Between HCP2202 and Co-administration of Each Component in Healthy Volunteers Under Fed ConditionsCompletedNCT05548543Phase 1
- A Study to Evaluate the PK, Safety and Tolerability of HCP1803.CompletedNCT05723549Phase 1
- A Study to Evaluate the Drug-drug Interaction and Safety of RLD2301 and RLD2007 in Healthy VolunteersCompletedNCT05862090Phase 1
- A Study to Evaluate the Pharmacokinetics and Safety Between HCP2001 and Co-administration of Each Component in Healthy VolunteersCompletedNCT05155995Phase 1
- Clinical Efficacy and Safety Evaluation of HCP1904-2 in Essential Hypertension PatientsCompletedNCT04830449Phase 3
- A Study to Evaluate the Pharmacokinetics and Safety Between HCP2202 and Co-administration of Each Component in Healthy VolunteersCompletedNCT05548387Phase 1
- A Study to Evaluate Pharmacokinetic/Pharmacodynamic Drug-drug Interaction and Safety/Tolerability Between RLD2202 and RLD2203CompletedNCT05481307Phase 1
- Clinical Efficacy and Safety Evaluation of HCP1904-1 in Essential Hypertension PatientsCompletedNCT04820907Phase 3
- HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid TumorsActive, not recruitingNCT03284502Phase 1
- Pharmacokinetic Drug Interactions Between HGP1607 and HGP1501CompletedNCT03089112Phase 1
- Safety to Evaluate the Efficacy and Safety of HIP1601 in Patients With Non Erosive Reflux DiseaseCompletedNCT04325620Phase 3
- Food-effect on PK and PD of Single Oral Dose of HIP1601 in Healthy SubjectsCompletedNCT04204629Phase 1
- An Observational Study to Evaluate the Treatment of Newvast® Tab(Atorvastatin) in Korean Patients With DyslipidemiaCompletedNCT05555238